Introduction {#s1}
============

Systemic lupus erythematosus (SLE) is a chronic and severe systemic autoimmune disease involving multiple organs/tissues, characterized by the production of antinuclear autoantibodies, complement and interferon activation, and tissue destruction ([@B1]--[@B3]). SLE could occur at any age, particularly during childbearing years and predominantly affecting women (at a 9:1 ratio) ([@B2]). Up to now, no single cause for SLE has been identified. Epidemiological evidence, together with recent linkage and association studies, have demonstrated that the interactions between predisposing genetic factors and environmental components are hypothesized to contribute to the pathogenesis of SLE ([@B4]--[@B8]).

Midkine (MK), representing as the founding member of heparin-binding growth factor family, was initially identified as the product of the *MK* gene, which is 1.5 kb in size and located on chromosome 11q11.2 ([@B9], [@B10]). MK has a similar structure and shares 50% homology in amino acid sequence with pleiotrophin (PTN) ([@B11]). MK and PTN are the only cytokines that constitute the *PTN*/*MK* developmental gene family and show a biological activity including the promotion of growth, cell migration, tissue morphogenesis, and chemokine expression in numerous target cell types ([@B12], [@B13]). During the past few years, increasing evidences suggested an essential role of MK and PTN in carcinomas and acute and chronic inflammatory diseases ([@B14]--[@B16]). Studies have demonstrated that MK and PTN are involved in several types of carcinomas; the overexpression of MK or PTN correlated with a poor prognosis for patients with neuroblastomas, urinary bladder carcinomas, and papillary thyroid cancer ([@B17]--[@B20]). Furthermore, studies have shown an association of intronic polymorphism of *MK* gene with human sporadic colorectal and gastric cancers ([@B21], [@B22]). In postmenopausal women, *PTN* gene promoter −1227C\>T (rs321198) polymorphism contributed to the genetic background of osteoporosis ([@B23]).

In rheumatoid arthritis (RA), a study has found an increased serum MK level in RA patients and its correlation with disease activity score (DAS) 28-erythrocyte sedimentation rate (ESR) and rheumatoid factors (RFs) titer ([@B24]). Our previous study has revealed that, as compared to healthy controls, the levels of plasma MK and PTN are elevated in SLE and also associated with interleukin (IL)-17 levels and some clinical manifestations, including rash and anti-Sjögren\'s-syndrome-related antigen A (anti-SSA) ([@B25]). These findings suggest a potential role of MK and PTN involved in certain types of autoimmune diseases.

Although study has unveiled the genetic association of *MK* and *PTN* in human cancer, the association between common single-nucleotide polymorphisms (SNPs) in the *MK* and *PTN* genes and SLE susceptibility has not yet been elucidated. Therefore, the present study was undertaken to comprehensively evaluate the role of common genetic variations in *MK* and *PTN* gene with SLE susceptibility in a Chinese population.

Materials and Methods {#s2}
=====================

Study Population
----------------

This case--control genotyping study consisted of 989 study subjects. Four hundred ninety-six SLE patients were recruited from the Department of Rheumatology and Immunology at Anhui Provincial Hospital, the First Affiliated Hospital of Anhui Medical University. All patients were diagnosed based on a strict medical history and immunological autoantibody screening results, as well as with at least four 1997 American College of Rheumatology (ACR) revised criteria for SLE; in addition, an attending rheumatologist (Xiao-Mei Li) was also invited to confirm the diagnosis of SLE. The patients were then classified based on the 1997 revised ACR classification criteria ([@B26], [@B27]). Individual disease activity was quantified using the SLE Disease Activity Index 2000 (SLEDAI-2K) score ([@B28], [@B29]). The disease activity of SLE was stratified according to SLEDAI-2K score, of which a SLEDAI-2K score of ≥10 or \<10 was defined as more active or less active, respectively ([@B30]). Four hundred ninety-three geographically and ethnically matched healthy controls were enrolled in the current study. All of the healthy controls did not have any inflammatory/autoimmune diseases history. Demographics, clinical manifestations, and laboratory findings were collected from hospital medical records and then reviewed by experienced physicians.

The Ethical Committee of Anhui Medical University (Hefei, Anhui, China) approved this study. The present study was conducted in accordance with the Declaration of Helsinki. All subjects, both cases and controls, provided informed consent to participate in this study.

SNP Screening and Genotyping
----------------------------

We used Ensembl Gene Browser 37 (<http://grch37.ensembl.org/index.html>) to acquire the detailed genetic and location information of human *MK* and *PTN* genes ([@B31]), and downloaded the linkage pedigree file (PED) and marker information file in Chinese Han population (CHB) of Beijing. Then, candidate tag SNPs selection was applied by utilizing the Haploview 4.2 software (Broad Institute, Cambridge, MA, United States), with the linkage disequilibrium *r*^2^ ≥ 0.80 and minor allele frequency (MAF) ≥ 5%. In total, 41 candidate tag SNPs (2 MK tag SNPs, 39 PTN tag SNPs) were chosen based on prior criteria. The online bioinformatics tools (<https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html>) were implemented to predict the function of 41 tag SNPs ([@B32]), including potentially deleterious functional impact at the splicing, transcriptional, translational, and post-translational level, as shown in [Table S1](#SM1){ref-type="supplementary-material"}.

In addition, relevant literatures reporting SNPs regarding *MK* and *PTN* gene polymorphisms were also reviewed. Finally, in our study cohort, we included three tag SNPs (rs116869512, rs20542, and rs35324223) in *MK* gene and seven tag SNPs (rs161335, rs321198, rs322236, rs3959914, rs6970141, rs919581, and rs322297) in *PTN* gene for further genotyping. The detailed information regarding the location of the SNPs within each gene locus is displayed in [Table S2](#SM2){ref-type="supplementary-material"}.

Plasma MK and PTN Detections
----------------------------

Intravenous blood samples (5 ml) of SLE patients were collected; the plasma sample was extracted and then frozen at −80°C in a refrigerator until assayed. Determinations of MK and PTN concentrations in plasma were performed using enzyme-linked immunosorbent assay (ELISA) kits (purchased from Anhui Xinle Biotechnology Co. LTD; expressed as pg/ml).

Statistical Analysis
--------------------

Comparisons of genotype and allele frequencies of SNPs between cases and controls were undertaken using chi-square or Fisher\'s exact test. Differences in plasma MK and PTN levels between different genotypes were compared using non-parametric test. The unconditional logistic regression model was used to estimate the associations between genotypes and SLE susceptibility. Three models were considered for statistical analysis, including additive, dominant, and recessive models. Statistical analysis was performed with the use of the Statistical Package for the Social Sciences (SPSS) statistical software, version 23.0 (SPSS Inc., Chicago, IL, United States).

Hardy--Weinberg equilibrium (HWE) and haplotype analyses were implemented using the SHEsis software (<http://analysis.bio-x.cn/myAnalysis.php>) ([@B33]). All statistical tests with two-tailed *P* \< 0.05 values were considered statistically significant. The Bonferroni correction was used for multiple testing to reduce the chances of obtaining false-positive results.

Results {#s3}
=======

Basic Characteristics of Study Subjects
---------------------------------------

This study recruited 496 SLE patients and 493 healthy controls. In SLE patients, there were 438 female and 58 male with an average age of 37.58 ± 11.44 years; the disease duration was 5.78 ± 5.59 years, and the average SLEDAI-2K scores were 11.40 ± 9.07. In addition, the body mass index (BMI) for patients was 21.83 ± 3.17. As for healthy controls, there were 434 female and 59 male with an average age of 38.45 ± 11.32 years. The age and gender distribution showed no significant differences between cases and controls. Demographic characteristics and clinical features of study subjects are summarized in [Table 1](#T1){ref-type="table"}. The major clinical features of SLE patients comprised immunological disorder (73.2%), hematological disorder (68.1%), malar rash (54.6%), arthritis (49.4%), photosensitivity (31.1%), and renal disorder (37.1%) ([Table 1](#T1){ref-type="table"}). In healthy controls, the presence of observed genotype frequency distributions of all included tag SNPs were not significantly different from the HWE at the 5% level.

###### 

Demographic characteristics and clinical features of patients with SLE and control subjects.

  **Parameters**                    **Patients with SLE (*n* = 496)**   **Healthy controls (*n* = 493)**
  --------------------------------- ----------------------------------- ----------------------------------
  **Demographic characteristics**                                       
  Age (years)                       37.58 ± 11.44                       38.45 ± 11.32
  Female, *n* (%)                   438 (88.3)                          434 (88.0)
  Male, *n* (%)                     58 (11.7)                           59 (12.0)
  Disease duration (year)           5.78 ± 5.59                         NA
  BMI (kg/m^2^)                     21.83 ± 3.17                        NA
  SLEDAI-2K                         11.40 ± 9.07                        NA
  **Disease manifestations**                                            NA
  Malar rash, *n* (%)               271 (54.6)                          NA
  Discoid rash, *n* (%)             94 (19.0)                           NA
  Photosensitivity, *n* (%)         194 (31.1)                          NA
  Oral ulcers, *n* (%)              119 (24.0)                          NA
  Arthritis, *n* (%)                245 (49.4)                          NA
  Serositis, *n* (%)                45 (9.1)                            NA
  Renal disorder, *n* (%)           184 (37.1)                          NA
  Neurological disorder, *n* (%)    21 (4.2)                            NA
  Hematological disorder, *n* (%)   338 (68.1)                          NA
  Immunological disorder, *n* (%)   363 (73.2)                          NA

*BMI, body mass index; n, number; SLE, systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000*.

Association of MK and PTN Gene Polymorphisms With Susceptibility to SLE
-----------------------------------------------------------------------

The genotype and allele frequencies of *MK* and *PTN* genes in SLE and healthy controls are shown in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}. In *MK* gene, there was no significant difference in genotype and allele distributions of three tag SNPs in SLE patients compared to healthy controls ([Table 2](#T2){ref-type="table"}). When analyzing seven tag SNPs in *PTN* gene, we did not find any significant differences in genotype and allele frequencies between SLE patients and healthy controls ([Table 3](#T3){ref-type="table"}).

###### 

Genotype frequency of *MK* SNPs in SLE patients and healthy controls.

  **SNPs**      **Analyzed model**        **SLE**   **Control**   ***P-*value[^\*^](#TN1){ref-type="table-fn"}**
  ------------- -------------------- ---- --------- ------------- ------------------------------------------------
  rs116869512   Genotypes            CC   448       452           0.999
                                     CA   45        41            0.999
                                     AA   3         0             
                Additive model       CC   448       452           0.999
                                     AA   3         0             
  rs20542       Genotypes            GG   424       420           0.725
                                     GA   67        70            0.494
                                     AA   5         3             
                Additive model       GG   424       420           0.725
                                     AA   5         3             
  rs35324223    Genotypes            AA   434       421           0.405
                                     AG   52        65            0.596
                                     GG   2         4             
                Additive model       AA   434       421           0.405
                                     GG   2         4             

*SLE, systemic lupus erythematosus; SNPs, single nucleotide polymorphisms; MK, midkine*.

*The P-values are not corrected for multiple testing, Bonferroni corrected P = 0.005*.

###### 

Genotype frequency of *PTN* SNPs in SLE patients and healthy controls.

  **SNPs**    **Analyzed model**        **SLE**   **Control**   ***P-*value[^\*^](#TN2){ref-type="table-fn"}**
  ----------- -------------------- ---- --------- ------------- ------------------------------------------------
  rs161335    Genotypes            CC   164       182           0.383
                                   CT   255       239           0.990
                                   TT   77        72            
              Additive model       CC   164       182           0.383
                                   TT   77        72            
  rs321198    Genotypes            CC   161       163           0.901
                                   CT   253       245           0.704
                                   TT   82        85            
              Additive model       CC   161       163           0.901
                                   TT   82        85            
  rs322236    Genotypes            AA   453       437           0.999
                                   GA   38        56            0.999
                                   GG   5         0             
              Additive model       AA   453       437           0.062
                                   GG   5         0             
  rs3959914   Genotypes            CC   155       155           0.862
                                   CT   245       244           0.871
                                   TT   95        92            
              Additive model       CC   155       155           0.862
                                   TT   95        92            
  rs6970141   Genotypes            TT   450       452           0.998
                                   CT   45        39            0.569
                                   CC   1         1             
              Additive model       TT   450       452           0.998
                                   CC   1         1             
  rs919581    Genotypes            AA   338       344           0.819
                                   GA   143       135           0.977
                                   GG   15        14            
              Additive model       AA   338       344           0.819
                                   GG   15        14            
  rs322297    Genotypes            TT   493       493           0.999
                                   TG   3         0             

*SLE, systemic lupus erythematosus; SNPs, single nucleotide polymorphisms; PTN, pleiotrophin*.

*The P-values are not corrected for multiple testing, Bonferroni corrected P = 0.005*.

Association of MK and PTN Gene Polymorphisms With Clinical Manifestations in SLE
--------------------------------------------------------------------------------

To unveil the possible genetic associations in *MK* and *PTN* gene polymorphisms with clinical manifestations, case-only analysis was applied. In *MK* gene, as shown in [Table 4](#T4){ref-type="table"}, the frequency of AA/AG genotype (rs35324223) was significantly lower in patients with photosensitivity than those without (*P* = 0.012). The allele frequency of A/G (rs20542) was significantly higher in patients without serositis (*P* = 0.042). In *PTN* gene, the A/G allele frequency (rs322236), C/T allele frequency (rs6970141), and TT/CT genotype frequency appeared significantly increased risks in patients with immunological disorder compared to those without (*P* = 0.020, *P* = 0.027, *P* = 0.035, respectively) ([Table 5](#T5){ref-type="table"}). However, there were no significant associations for other tag SNPs in *MK* and *PTN* genes with clinical disease manifestations.

###### 

The positive findings on association of clinical characteristics with genotype and allele frequencies in *MK*.

  **SNPs**     **Allele (M/m)**   **Clinical features**   **Group**   **Genotypes (*****n*****)**   **OR (95% CI)**   ***P-*value**   **Alleles (*****n*****)**   **OR (95% CI)**   ***P-*value**                                
  ------------ ------------------ ----------------------- ----------- ----------------------------- ----------------- --------------- --------------------------- ----------------- --------------- ----- ---------------------- -----------
  rs35324223   A/G                Photosensitivity        Positive    175                           13                2               0.493 (0.256, 0.951)        **0.012**         363             17    0.669 (0.373, 1.200)   0.205
                                                          Negative    259                           39                0                                                             557             39                           
  rs20542      A/G                Serositis               Positive    1                             10                34              0.698 (0.480, 1.016)        0.090             12              78    0.505 (0.261, 0.975)   **0.042**
                                                          Negative    4                             57                390                                                           65              837                          

*Values in bold show significance*.

*SNPs, single nucleotide polymorphisms; OR, odds ratio; MK, midkine*.

###### 

The positive findings on association of clinical characteristics with genotype and allele frequencies in *PTN*.

  **SNPs**    **Allele (M/m)**   **Clinical features**    **Group**   **Genotypes (*****n*****)**   **OR (95% CI)**   ***P-*value**   **Alleles (*****n*****)**   **OR (95% CI)**   ***P-*value**                                
  ----------- ------------------ ------------------------ ----------- ----------------------------- ----------------- --------------- --------------------------- ----------------- --------------- ----- ---------------------- -----------
  rs322236    A/G                Immunological disorder   Positive    337                           24                2               1.297 (0.663, 2.537)        0.068             698             28    2.027 (1.121, 3.663)   **0.020**
                                                          Negative    116                           14                3                                                             246             20                           
  rs6970141   C/T                Immunological disorder   Positive    1                             39                323             2.621 (1.085, 6.334)        **0.035**         41              685   2.594 (1.088, 6.182)   **0.027**
                                                          Negative    0                             6                 127                                                           6               260                          

*Values in bold show significance*.

*SNPs, single nucleotide polymorphisms; OR, odds ratio; PTN, pleiotrophin*.

Association of Plasma MK and PTN Levels With Its Genotypes
----------------------------------------------------------

The results indicated that, in patients with SLE, there were no significant differences in plasma MK and PTN concentrations with its tag SNPs genotypes ([Tables 6](#T6){ref-type="table"}, [7](#T7){ref-type="table"}).

###### 

Association of plasma MK levels with genotype in *MK* gene.

  **SNPs**      **Genotypes**   **Number**   **Plasma MK levels (pg/ml)**   ***P*-value**
  ------------- --------------- ------------ ------------------------------ ---------------
  rs116869512   CA              9            1651.18 (1199.71, 2684.59)     0.250
                CC              75           2085.79 (1627.88, 2610.80)     
  rs20542       GA              13           1944.15 (1618.05, 2621.05)     0.771
                AA              1            2008.56                        
                GG              70           2074.96 (1611.07, 2618.65)     
  rs35324223    AG              7            1639.78 (1608.53, 1657.19)     0.271
                AA              76           2074.96 (1613.76, 2648.43)     
                GG              1            2610.80                        

*SNPs, single nucleotide polymorphisms; M, median; MK, midkine*.

###### 

Association of plasma PTN levels with genotype in *PTN* gene.

  **SNPs**    **Genotypes**   **Number**   **Plasma PTN levels (pg/ml)**   ***P*-value**
  ----------- --------------- ------------ ------------------------------- ---------------
  rs161335    CT              47           762.52 (698.84, 943.86)         0.303
              CC              24           704.67 (666.77, 820.88)         
              TT              13           766.78 (673.57, 846.91)         
  rs321198    TC              42           742.85 (682.69, 912.54)         0.802
              CC              31           763.50 (691.60, 914.56)         
              TT              11           723.56 (666.06, 887.05)         
  rs322236    GA              5            761.56 (689.55,856.13)          0.605
              AA              79           738.07 (681.00, 902.10)         
  rs322297    TT              84           742.85 (681.56, 899.32)         --
  rs3959914   CT              42           754.60 (687.50, 919.94)         0.946
              CC              24           718.32 (652.19, 847.07)         
              TT              18           795.18 (668.69, 912.54)         
  rs6970141   CT              6            846.45 (676.32, 906.04)         0.824
              CC              1            651.23                          
              TT              77           738.07 (683.77, 908.33)         
  rs919581    GA              25           761.56 (691.93, 939.20)         0.909
              AA              55           732.46 (674.15, 886.98)         
              GG              4            744.21 (696.38, 898.53)         

*SNPs, single nucleotide polymorphisms; M, median; PTN, pleiotrophin*.

Haplotype Analyses
------------------

We have constructed four main haplotypes (AAA, CAA, CGA, and CGG) for *MK* gene and eight main haplotypes (CCATCTA, CCATTTG, CTATCTA, CTATTTA, CTATTTG, TCATCTA, TCATTTA, and TCATTTG) for *PTN* gene using SHEsis software. The results revealed that *MK* and *PTN* genes haplotypes were not associated with SLE susceptibility ([Tables 8](#T8){ref-type="table"}, [9](#T9){ref-type="table"}).

###### 

Haplotype analysis of three SNPs in *MK* gene in SLE patients and healthy controls.

  **Haplotype**                      **SLE \[*n* (%)\]**   **Controls \[*n* (%)\]**   **χ^**2**^**   ***P*-value**   **OR (95% CI)**
  ---------------------------------- --------------------- -------------------------- -------------- --------------- ----------------------
  rs116869512--rs20542--rs35324223                                                                                   
  AAA                                45.86 (4.7)           39.23 (4.0)                0.588          0.443           1.186 (0.767, 1.833)
  CAA                                27.99 (2.9)           35.04 (3.6)                0.766          0.381           0.798 (0.482, 1.323)
  CGA                                842.09 (86.5)         830.73 (84.9)              1.222          0.269           1.156 (0.894, 1.495)
  CGG                                52.85 (5.4)           70.22 (7.2)                2.496          0.114           0.744 (0.514, 1.075)

*Total χ^2^ = 3.811, P = 0.282. All the haplotypes with a frequency \< 0.03 were ignored in the analysis*.

*SLE, systemic lupus erythematosus; SNPs, single nucleotide polymorphisms; MK, midkine; OR, odds ratio*.

###### 

Haplotype analysis of seven SNPs in *PTN* gene in SLE patients and healthy controls.

  **Haplotype**                                                            **SLE \[*n* (%)\]**   **Control \[*n* (%)\]**   **χ^**2**^**   ***P-*value**   **OR (95% CI)**
  ------------------------------------------------------------------------ --------------------- ------------------------- -------------- --------------- ----------------------
  rs161335--rs321198--rs322236--rs322297--rs3959914--rs6970141--rs919581                                                                                  
  CCATCTA                                                                  81.52 (8.2)           97.66 (9.9)               1.867          0.171           0.806 (0.591, 1.099)
  CCATTTG                                                                  51.11 (5.4)           48.59 (4.9)               0.154          0.694           1.084 (0.726, 1.618)
  CTATCTA                                                                  126.09 (12.7)         128.94 (13.1)             0.095          0.758           0.959 (0.735, 1.251)
  CTATTTA                                                                  202.14 (20.4)         211.45 (21.5)             0.460          0.497           0.926 (0.743, 1.155)
  CTATTTG                                                                  49.37 (5.0)           47.41 (4.8)               0.019          0.890           1.029 (0.683, 1.551)
  TCATCTA                                                                  294.27 (29.7)         279.44 (28.5)             0.314          0.575           1.059 (0.867, 1.293)
  TCATTTA                                                                  31.93 (3.2)           21.83 (2.2)               1.823          0.177           1.460 (0.840, 2.538)
  TCATTTG                                                                  44.04 (4.4)           35.48 (3.6)               0.848          0.357           1.236 (0.786, 1.944)

*Total χ^2^ = 5.061, P = 0.653. All the haplotypes with a frequency \< 0.03 were ignored in the analysis*.

*SLE, systemic lupus erythematosus; SNPs, single nucleotide polymorphisms; PTN, pleiotrophin; OR, odds ratio*.

Discussion {#s4}
==========

MK and PTN comprise a two-member family of heparin-binding cytokines. Previous studies have demonstrated that MK and PTN can be highly expressed in various human cancers and play a key role in the promotion of cancer cell survival, proliferation, and angiogenesis, contributing to tumor growth. *MK* gene promoter contains a putative nuclear factor-kappa B (NF-kB)-responsive element that can drive the induction of MK ([@B34]). In the early of 2000, Ahmed et al. has examined the entire coding region, four regions of the promoter and eight sets of intron-based and promoter region primers; they found that, in the *MK* promoter region, mainly a G/T polymorphism (G to T transition) at the 62 nd base of intron 3, there was a higher G/T genotype frequency in colorectal cancers, suggesting that this G/T genotype might be a risk factor contributing to the carcinoma in the colon and rectum ([@B35], [@B36]). However, Lai et al. reported that the genetic variation of *MK* gene (rs20542) was not associated with sporadic gastric cancers ([@B21]).

For PTN, interferon (IFN)-g could positively regulate and promote the expression of PTN via an IFN-g-responsive promoter element ([@B37]). Besides, hyaluronan (HA) has been shown to inhibit the toll-like receptor (TLR) 4 activity to downregulate PTN level in a Th1-type autoimmune disease model, implicating *PTN* as a TLR4-responsive gene ([@B38]). Mencej-Bedrac et al. has addressed the relationship of *PTN* gene with osteoporosis; they found that the *PTN* gene rs321198 polymorphisms and its CT haplotype were associated with genetic susceptibility of osteoporosis in postmenopausal women ([@B23]).

It has also been disclosed that MK plays critical roles in several types of inflammatory diseases. MK was expressed by macrophage- and fibroblast-like cells of the synovial membrane. Enhanced MK levels on both synovial fluid and sera were present in RA patients, and the increase in MK level positively correlated with RF ([@B24]). In RA patients with active inflammatory synovitis, the inflamed tissues showed an overexpression of MK, while a non-inflamed tissue had no MK expression at all ([@B39]).

We previously reported elevated plasma MK and PTN concentrations in SLE compared with healthy controls, and the increase in MK and PTN levels correlated with inflammatory cytokine IL-17 and some clinical features/parameters, including rash and anti-SSA antibody, suggesting that an aberrant expression of MK and PTN might be involved in the progress of inflammation and the course of SLE ([@B25]).

In the present study, we investigated the association of *MK* and *PTN* gene SNPs and its susceptibility to SLE in a Chinese population. A total of 10 tag SNPs of *MK* and *PTN* genes were genotyped and analyzed; however, we did not find any significant associations of 10 tag SNPs with SLE susceptibility. In addition, we also performed a case-only analysis to determine the relationship of 10 tag SNPs with the clinical features of SLE; our results showed that the SNPs in *MK* and *PTN* genes associated with some SLE clinical manifestations. In the *MK* gene, the frequency of AA/AG genotypes (rs35324223) was decreased in SLE patients with skin photosensitivity, suggesting that the lower AA/AG genotype of rs35324223 might correlate with decreased skin photosensitivity risk and play as a protective factor for the occurrence of skin photosensitivity. Moreover, we identified a decreased A/G (rs20542) allele frequency in patients with serositis; the decreased A/G allele frequency appeared to be protective against serositis in SLE. In the *PTN* gene, we found that two SNPs (rs322236 and rs6970141) associated with an increased risk for immunological disorder in SLE; the A allele of rs322236, T allele, and TT/CT genotype of rs6970141 were the risk alleles of immunological disorder, contributing to the disease clinical features. To observe the possible associations of *MK* and *PTN* SNPs with their plasma protein levels, we analyze the differences in plasma MK and PTN levels in different genotypes of each tag SNPs, but there were no correlations between plasma levels of MK and PTN levels and its tag SNPs. At last, the haplotype analysis in our study revealed no significant differences in *MK* and *PTN* gene haplotypes. Taken together, although there were no associations of the 10 tag SNPs in *MK* and *PTN* genes with SLE susceptibility, we have revealed that there are some SNPs that interact together in modulating the risk toward clinical manifestation of skin photosensitivity, serositis, and immunological disorder in SLE.

To the best of our knowledge, this is the first study to investigate the association of *MK* and *PTN* gene SNPs with SLE susceptibility. Nevertheless, several shortcomings of the present study should be acknowledged. First, only part of the patients had plasma MK and PTN measurements, which may cause the potential bias. Second, only common variants in *MK* and *PTN* genes were examined; it may reduce the effect of these SNPs in their association analyses. Furthermore, in the present study, only Chinese Han population was included; it may restrict the generalizability of our results.

Conclusions {#s5}
===========

Overall, results from the present study revealed that *MK* and *PTN* gene polymorphisms have no associations with SLE genetic susceptibility; however, we found associations of some tag SNPs with specific SLE clinical manifestations, suggesting that *MK* and *PTN* genes associated with the course of SLE. However, further studies with a larger study sample size and more ethnic lines covering the entire gene variability of both *MK* and *PTN* genes are still required to confirm our results.
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